(Q36563631)

14 August 2017

1 reference

title

Prostate-specific antigen and detection of prostate cancer: What have we learned and what should we recommend for screening? (English)

1 reference

14 August 2017

1 reference

Christopher L Amling

1

1 reference

14 August 2017

publication date

1 September 2006

1 reference

Current Treatment Options in Oncology

14 August 2017

published in

1 reference

14 August 2017

volume

7

1 reference

14 August 2017

issue

5

1 reference

14 August 2017

page(s)

337-345

1 reference

Asymptomatic incidence and duration of prostate cancer

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11864-006-0001-1

Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-006-0001-1

Viewpoint: expanding prostate cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-006-0001-1

Estimating treatment benefits for the elderly: the effect of competing risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-006-0001-1

Pathological characteristics of prostate cancer detected through prostate specific antigen based screening

21 January 2018

1 reference

12 December 2020

Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup

1 reference

12 December 2020

The Pathological Features and Prognosis of Prostate Cancer Detectable With Current Diagnostic Tests

1 reference

12 December 2020

Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA)

1 reference

12 December 2020

A prospective study of physical activity and risk of prostate cancer in US physicians

1 reference

12 December 2020

Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates

1 reference

12 December 2020

Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial

1 reference

12 December 2020

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

1 reference

12 December 2020

Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker

1 reference

12 December 2020

A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer

1 reference

12 December 2020

Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml

1 reference

12 December 2020

Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection

1 reference

12 December 2020

Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease

1 reference

12 December 2020

Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends

1 reference

12 December 2020

Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer

1 reference

12 December 2020

Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial

1 reference

12 December 2020

Complexed Prostate Specific Antigen Improves Specificity for Prostate Cancer Detection: Results of a Prospective Multicenter Clinical Trial

1 reference

12 December 2020

Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves.

1 reference

12 December 2020

Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen

1 reference

12 December 2020

Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial

1 reference

12 December 2020

Prostate cancer mortality reduction by screening: Power and time frame with complete enrollment in the European randomised screening for prostate cancer (ERSPC) trial

1 reference

12 December 2020

The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen

1 reference

12 December 2020

Prostate-specific antigen test use reported in the 2000 National Health Interview Survey

1 reference

12 December 2020

Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges

1 reference

12 December 2020

Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml

1 reference

12 December 2020

Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves.

1 reference

12 December 2020

Do older men benefit from curative therapy of localized prostate cancer?

1 reference

12 December 2020

Cancer screening guidelines

1 reference

12 December 2020

Interpreting recent trends in prostate cancer incidence and mortality

1 reference

12 December 2020

Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria

1 reference

12 December 2020

American Cancer Society guidelines for the early detection of cancer, 2006.

1 reference

12 December 2020

Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial

1 reference

12 December 2020

Screening for prostate cancer: have you had your cholesterol measured?

1 reference

12 December 2020

Detection of Organ-Confined Prostate Cancer Is Increased Through Prostate-Specific Antigen—Based Screening

1 reference

12 December 2020

Screening for prostate cancer: current recommendations

1 reference

12 December 2020

Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease

1 reference

12 December 2020

Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study

1 reference

12 December 2020

Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower

1 reference

12 December 2020

Screening for prostate cancer: estimating the magnitude of overdetection

1 reference

12 December 2020

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

1 reference

12 December 2020

Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer

1 reference

12 December 2020

Overdiagnosis of prostate carcinoma by screening: an estimate based on the results of the Florence Screening Pilot Study

1 reference

12 December 2020

10.1007/S11864-006-0001-1

Identifiers

DOI

1 reference

14 August 2017

1 reference